OncoCyte Corporation (OCX) (OCX) revealed Loss for fourth quarter of -$33.51 million
The company's bottom line came in at -$33.51 million, or -$1.93 per share. This compares with -$15.99 million, or -$1.96 per share, last year.
The company's revenue for the period rose 373.2% to $1.486 million from $0.314 million last year.
OncoCyte Corporation (OCX) earnings at a glance (GAAP) :
-Earnings: -$33.51 Mln. vs. -$15.99 Mln. last year.-EPS: -$1.93 vs. -$1.96 last year.-Revenue: $1.486 Mln vs. $0.314 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.